Document Detail


Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
MedLine Citation:
PMID:  22879789     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.
Authors:
Jay Shubrook; Randall Colucci; Aili Guo; Frank Schwartz
Related Documents :
9449399 - Acute effects of blood pressure elevation on insulin clearance in normotensive healthy ...
10487669 - Metabolic effects of short-term elevations of plasma cortisol are more pronounced in th...
7476299 - Fish oil feeding improves muscle glucose uptake in tumor necrosis factor-treated rats.
22585619 - Effect of zinc supplementation on type 2 diabetes parameters and liver metallothionein ...
20028969 - Metabolic effects of intensive insulin therapy in critically ill patients.
2673569 - Adenosine restores myocardial responsiveness to insulin during acute endotoxin shock in...
21152029 - Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin re...
7042509 - Preparation and properties of covalently linked insulin dimers.
17188609 - Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intr...
Publication Detail:
Type:  Journal Article     Date:  2011-01-12
Journal Detail:
Title:  Clinical medicine insights. Endocrinology and diabetes     Volume:  4     ISSN:  1179-5514     ISO Abbreviation:  Clin Med Insights Endocrinol Diabetes     Publication Date:  2011  
Date Detail:
Created Date:  2012-08-10     Completed Date:  2012-08-23     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101578235     Medline TA:  Clin Med Insights Endocrinol Diabetes     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1-12     Citation Subset:  -    
Affiliation:
Department of Family Medicine,OU-COM, 349 Grosvenor Hall, Athens OH 45701, Ohio University College of Osteopathic Medicine (OU-COM), Athens OH 45701.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.
Next Document:  The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 D...